RHD*01EL.01 - RHD*DEL1
(ISBT table: weak D and Del v5.0)

This entry is an RHD allele.

Asia type DEL, Asian DEL, K409K, RHD(1227G>A), RHD(K409K), RHD*1227A, RHD*1227A (DEL1), RHD*1227G>A,
Download VCF file

Molecular data

Nucleotides: 1227G>A;

Amino acids: K409K;

Hybrid allele encompassing at least one RHCE exon: no

Comments on the molecular basis:

  • initial descriptions erroneously described deletion of Exon 9
  • initial descriptions erroneously described deletion of Exon 9
  • RHD-specific miRNA expression level quantification
  • demonstrate that the intial descriptions describing deletion of Exon 9 were erroneous
  • zygosity determination by MPLA and RHbox detection
  • see also "Additional comments" section on the RhesusBase http://www.rhesusbase.info/RHDRHD(1227GtoA).htm
  • NGS

Extracellular position of one or more amino acid substitutions:

  • Silent or intronic mutations: none of the mutations are predicted to affect an extracellular amino acid.

Splicing:

  • unequivocal effect on splicing
  • unequivocal effect on splicing
  • effect on splicing, predicted in silico
  • demonstrated effect on splicing, study of aberrant splicing transcripts
  • effect on splicing assumed to be responsible for phenotype
  • splice site affected
  • splice site mutation
  • effect on splicing hypothized

Unconventional prediction methods:

Phenotype

Main D phenotype: DEL or D negative (last update: Jan. 6, 2021)
Reports by D phenotype
  • Discrepant D phenotype (negative or positive depending on anti-D reagents and techniques)
    • discordant between tube and IAT
  • Weak D phenotype
    • "weak/partial" phenotype
    • for samples heterozygous for RHef00283 and RHef00122
  • DEL
    • adsorption-elution was performed, 107 samples
    • study may overlap with 25960711; adsorption-elution was performed
    • study may overlap with 26033335; adsorption-elution was performed
    • adsorption-elution was performed
    • adsorption-elution was performed
    • adsorption-elution was performed
    • adsorption-elution was performed
    • adsorption-elution was performed
    • study may overlap with 24679597
    • adsorption-elution was performed
    • adsorption-elution was performed
    • adsorption-elution was performed
    • adsorption-elution was performed
    • ISBT classification
    • adsorption-elution was performed; overlaps with 999999913
    • adsorption-elution was performed; overlaps with 999999988
    • adsorption-elution was performed on at least one sample
    • adsorption-elution was performed
    • adsorption-elution was performed; 2 samples negative, 14 DEL
    • listed as DEL but adsorption-elution was not performed
    • adsorption-elution was performed
  • D negative
    • adsorption-elution was performed, 21 samples
    • adsorption-elution was not performed
    • adsorption-elution was not performed
    • adsorption-elution was not performed
    • adsorption-elution was not performed
    • article states that adsorption-elution was performed but results with this method are not clear
    • adsorption-elution was not performed
    • article states that adsorption-elution but results are not presented
    • adsorption-elution was not performed
    • study may overlap with 24656493; adsorption-elution was not performed
    • adsorption-elution was not performed
    • adsorption-elution not specified
    • adsorption-elution was performed
    • adsorption-elution was performed; 2 samples negative, 14 DEL
    • adsorption-elution was not performed
    • 28 samples, including by IAT; adsorption-elution was not performed
    • adsorption-elution was not performed
    • article states that adsorption-elution was performed, but for which samples it was done for is not clear
Other RH phenotypes: RH:-2, -3, -4, -5,
  • RH:-2 inferred from the reported RHCE phenotypes of the carriers
  • RH:-3 inferred from the reported RHCE phenotypes of the carriers
  • RH:-4 inferred from the reported RHCE phenotypes of the carriers
  • RH:-5 inferred from the reported RHCE phenotypes of the carriers
Serology with monoclonal anti-D
  • 18 monoclonal Ab tested
  • normal D positive phenotype by epitope pattern mapping by adsorption-elution using 16 monoclonal anti-D (study may overlap with 25960711)
  • tested with Diagast Dscreen kit
  • 21 anti-D tested, results not detailed
  • epitope pattern mapping by adsorption-elution, all anti-D tested could be eluted
  • negative, with a panel of 10 monoclonal anti-D
Antigen Density (Ag/RBC)
  • <22 Ag/RBC, 2 samples
  • 22 Ag/RBC, compared to a standard CcDdee RBC sample with 9748 D sites per RBC, 154 samples tested
  • 22 Ag/RBC, 2 samples
More phenotype data
Rhesus Similarity Index

Haplotype

Main CcEe phenotype association: Ce is the most frequent association, ce is less frequent (last update: July 28, 2020)
Number of samples reported by haplotype
ce Ce cE CE
ce 27 1148 26 0
Ce 235 177 7
cE 0 1
CE 2
Reports by CcEe phenotype
  • with Ce
    • 18 samples
    66 samples (15 samples homozygous for allele and haplotype)
    3 samples
    2 samples (1 sample homozygous)
    1 sample
    51 samples
    30 samples (11 homozygous, 4 heterozygous with RHef00448 or other)
    4 samples (4 samples, haplotype given, not complete phenotype) (haplotype given, not complete phenotype; not all samples could be counted)
    10 samples (study may overlap with 26033335)
    5 samples (haplotype given, not complete phenotype)
    14 samples
    31 samples (at least 31 samples, maybe 32; haplotype given not complete phenotype)
  • with Ccee
    • 3 samples
    1 sample (study may overlap with 24679597)
    2 samples (study may overlap with 24656493) (considering RHCE genotyping, RHD zygosity and RHD allele, R1 was considered the most likely haplotype)
    4 samples
    5 samples
    31 samples
    130 samples
    363 samples (including 34 samples homozygous for allele)
    32 samples (including 2 homozygous for the allele)
    12 samples
    36 samples
    97 samples
    15 samples
    166 samples
    150 samples (study may overlap with 26033335)
    16 samples
    78 samples
    7 samples
  • with ce
    • 1 sample (1 sample homozygous)
    24 samples
    2 samples (at least 2 samples, maybe 3; haplotype given not complete phenotype)
  • with cCEE
    • 1 sample
  • with ccEe
    • 3 samples
    20 samples
    1 sample
    2 samples (study may overlap with 26033335)
  • with CE
    • 2 samples (haplotype given, not complete phenotype; not all samples could be counted)
  • with CCEe
    • 1 sample
    2 samples
    4 samples (study may overlap with 26033335)
  • with CcEe
    • 6 samples
    43 samples
    4 samples
    1 sample
    2 samples (study may overlap with 26033335)
    121 samples
Main allele association:
Reports by allele association
  • RHCE*Ce or RHCE*ce
    • 1 sample

Alloimmunization

Antibodies in carriers
Antibody specificity: D (RH1)
Summary: no published cases (last update: Jan. 6, 2021)
Detailed information
    Wang M et al. Transfus Med (2015) (study may overlap with 25960711)
    Shao CP et al. Transfus Clin Biol (2010)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 0
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT: NA
  • Autologuous control: NA
  • Elution: NA
  • Autoadsorption: NA
  • Titer: NA
  • Was anti-LW excluded?: NA
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types): NA
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: pregnancy
  • Hemolytic consequences:
  • Comment: among pregnant women with DEL phenotype
    Shao CP et al. N Engl J Med (2010)
    Shao CP et al. Transfus Clin Biol (2010)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 0
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT: NA
  • Autologuous control: NA
  • Elution: NA
  • Autoadsorption: NA
  • Titer: NA
  • Was anti-LW excluded?: NA
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types): NA
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: pregnancy
  • Hemolytic consequences:
  • Comment: retrospective analysis of 104 pregnanices with confirmed anti-D, none had this allele despite an expected frequency of 1/3
    Wang QP et al. Blood Transfus (2014)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 0
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT:
  • Autologuous control:
  • Elution:
  • Autoadsorption:
  • Titer:
  • Was anti-LW excluded?:
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types):
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history:
  • Context:
  • Hemolytic consequences:
  • Comment:
    Shao CP et al. N Engl J Med (2010)
    Shao CP et al. Transfus Clin Biol (2010)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-): 0
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed: 44
  • DAT: NA
  • Autologuous control: NA
  • Elution: NA
  • Autoadsorption: NA
  • Titer: NA
  • Was anti-LW excluded?: NA
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types): NA
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: pregnancy
  • Hemolytic consequences:
  • Comment: prospective study of 199 apparent D negative pregnancies, 44 of which were RHef00122; 38 of the 155 true D negative women developped allo-anti-D, no RHef00122 developped allo-anti-D
    Kim H et al. Transfus Apher Sci (2019)
  • Ab specificity: D (RH1)
  • Number (auto- or allo-):
  • Number listed as allo-:
  • Number listed as auto-:
  • Number of carriers of the allele assessed:
  • DAT: NA
  • Autologuous control: NA
  • Elution: NA
  • Autoadsorption: NA
  • Titer: NA
  • Was anti-LW excluded?: NA
  • Other antibodies detected:
  • Cross matches (with Ab and RBCs from different partial types): NA
  • Transfusion history:
  • Pregnancy history:
  • Anti-D Ig history: ND, probably none
  • Context: pregnancy
  • Hemolytic consequences:
  • Comment: Authors consider it premature to transfuse carriers of this variant with D+ RBC units, point to the limitations of previous studies advocating for this measure, and mention an ongoing clinical trial https://clinicaltrials.gov/ct2/show/NCT03727230
Antibodies in D negative recipients

Alloimmunization in recipients: yes, see detailed reports and phenotype data

    Yang HS et al. Ann Lab Med (2015)
  • Ab specificity: D (RH1)
  • Number of cases: 1
  • Exposures: transfusion of 2 RBC units carrying this allele
  • Imputability:
  • Comment: anti-D developped 5 to 7 days after transfusion; considered primary immunization

Reports

Summary: common allele, mainly in Eastern Asian individuals or compatible with such descent (last update: Aug. 9, 2020)
Detailed reports
  • 5/8442 8442 donors with D negative phenotype, screened for presence of the RHD gene in two surveys; 754 donors were C and/or E positive, the rest were ccee phenotype; 5 donors were revealed to be weakly D positive in the German population, Baden-Wurttemberg
  • 2/3 samples with weak D phenotype in the Chinese population
  • 25/102 + 1/6 102 samples with D negative phenotype by IAT (118 D negative among 41.921 first time donors, DNA was available for 95; 7 D negative pregnant women), 76 were true D negative and 26 DEL phenotypes in the Chinese population (Shenzen area, 96% Chinese Han) (102 samples) (6 samples)
  • 94/294 D negative Taiwan Chinese
  • 21/74 (+1 not fully typed but assumed) donors with D negative phenotype (adsorption-elution was not performed) Chinese Han
  • 43/264 samples (or 42/528 alleles) donors with D negative phenotype Korean
  • 0/738 samples with D negative, but C and/or E positive phenotype, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the Austrian population, Tyrol
  • 0/104 samples with D negative, but C and/or E positive phenotype, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the Swiss population, Bern and the canton of Bern
  • 0/400 samples with D negative, but C and/or E positive phenotype, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the German (states of Lower Saxony, Saxony- Anhalt, Thuringia, Oldenburg, and Bremen) population
  • 0/71 samples with D negative, but C and/or E positive phenotype, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the Russian (Kirov Oblast) population
  • 0/333 samples with D negative, but C and/or E positive phenotype, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the Slovenian population
  • 0/54 samples with D negative, but C and/or E positive phenotype, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the German (city of Braunschweig and eastern parts of Lower Saxony) population
  • 3 samples Chinese Asian
  • 16/126 donors with D negative phenotype Korean, South Korea
  • 1/4 weak D phenotype Korean (South Korea)
  • 3/32 weak D or discordant between tube and IAT whithin a population of 305572 Chinese Han and minority donors Chinese Han
  • 2/86 donors with D negative phenotype Uigur Chinese
  • 11/50 donors with D negative phenotype Han Chinese
  • 1/7 donors with D negative phenotype Hui Chinese
  • 1/23330 donor samples with D negative phenotype tested for RHD exons 4, 7 and 10 (94 were PCR positive, 74 weak D or DEL in subsequent serologic analysis) in the Austrian population, Upper Austria
  • 4/96 among almost 3 million blood donations, 621685 had D negative phenotype; 46133 donors were first time donors with D negative phenotype and, when tested, 96 had RHD intron 4 in the German population
  • 268/279 of DEL phenotypes (or /400253 all phenotypes) among 400253 random donors, 1585 had apparent D negative phenotype, but among those, 279 were DEL in the Chinese population, Shanghai
  • 1/7 donors with D negative phenotype (out of donor population 22000), C or E positive (leaves: 233 donors) and amplification of RHD exon 10 (leaves:7) Danish
  • 5/101 among 2450 donors with D negative phenotype, tested for RHD specific polymorphisms (101 were positive for the polymorphisms) Asian descent in Brazilian, Southeast and Northeast Brazil
  • 31/34 donors with DEL phenotype, from a total of 30799 blood samples tested Chinese Anhui Han
  • 3/163 selected variants included for the development of a genotyping assay mainly in the Dutch population (samples may have been included in other studies)
  • 2/520 among 520 donors with D negative phenotype, C and/or E positive in the Brazilian population (Sao Paulo)
  • 154/160 DEL phenotype Chinese Han
  • 160/720 D negative phenotype Chinese Han
  • 518/2493 (467 heterozygous with RHef00446, 49 homozygous, 2 heterozygous with RHef00283) donors with apparent D negative phenotype (108/2493 were in fact weak D or DEL) Han Chinese, Shanxi Province, Central China
  • 1/26243 donors with D negative phenotype in three studies with different inclusion criteria in the Swiss population (Zurich and Berne) (study may overlap with 24679597)
  • 1/25370 donors with D negative phenotype, screened for RHD exons 3 or 7, plus 5 and 10 in the Swiss population (study may overlap with 24656493)
  • 37/42306 42306 donors were screened, of which 165 had apparent D negative phenotype, of which 41 were DEL phenotype and characterized at the molecular level East and South-East China
  • 16/2027 2027 donors with D negative phenotype, C and/or E positive, screened for RHD exons 4, 5 and 10 and for DEL phenotype in the Australian population
  • 8/32 donors suspected to have weak D or partial D phenotypes sent to a reference laboratory Chinese (Zhejiang Han)
  • 318/3526 donors with D negative phenotype (4 heterozygous) Japanese
  • 168/178 DEL phenotype pregnant women Han Chinese (study may overlap with 26033335)
  • 130/142 pregnant women with apparent D negative phenotype Han Chinese (study may overlap with 25960711)
  • 9/37782 270 women with variant alleles among 37782 women with D negative phenotype, tested by quantitative fetal RHD genotyping designed to detect RHD exons 5 and 7 in the Dutch population
  • 14/110 among members of the RhD-negative club Korean
  • 3/62 heterozyguous samples associated with another variant allele D variant donors Chinese, Southern Han
  • 45/200 (38 hemizygous, 3 homozygous, 4 heterozygous) donors with D negative phenotype, tested by MPLA Chinese, Southern Han
  • 5/200 (heterozygous with RHef00442) D positive donors tested by MPLA Chinese, Southern Han
  • 17/95 donors with apparent D negative phenotype Korean
  • 2/662 among 662 pregnant patients with apparent D negative phenotype, enroled for fetal genotyping Australia
  • 2/405 donors with D negative phenotype, C and/or E positive, with RHD gene present Brazilian
  • 4/1174 donors with D negative phenotype United States population (Los Angeles)
  • 1/517 in a population of 67428 random donors, 8042 had D negative phenotype, among those, 517 were C and/or E positive and were screened for RHD gene in the Brazilian population (Sao Paolo)
  • 8/45 (including 1 heterozygous with RHef00283, 1 with RHef00357, 1 with RHef00161, 1 with RHef00179, 1 with RHef00173) among 132479 donors screened, 45 had weak D phenotype in the northeastern Chinese Liaoning Province population
  • 28/117 (24 hemizygous, 3 homozygous, 1 heterozygous with RHef00707) among 132479 donors screened, 117 had D negative phenotype in the northeastern Chinese Liaoning Province population
  • 21/200 donors with D negative phenotype (DEL phenotype excluded) Thai
  • 24/129 (in trans with various alleles) donors with weak D phenotype Thai
  • 108/121 (including heterozygous with RHef00460) donors with DEL phenotype Thai
  • 7/185 RH:–1,–4 or RH:–1,–5 recipients reported by a French lab
  • 2 samples donors with apparent D negative phenotype Japanese
  • 11/136000 among about 136.000 donors with D negative phenotype, systematically tested for the presence of the RHD gene; the RHD gene was detected in 300 donors in the German population (some samples may overlap with other studies)
  • 4/46,756 first time donors with D negative phenotype, tested for RHD exon 7 and adsorption-elution with a polyclonal anti-D in the German population (Northern) (overlaps with 999999913; some samples may overlap with full publications) (overlaps with 999999988; some samples may overlap with 19243542)
  • 2/16,253 samples of pregnant women with D negative of weak D (2+ or less), screened for fetal RHD in the Finnish population
  • 1 hemizygote among 278 samples selected for the development of nonspecific quantitative next-generation sequencing. (non-random samples, may have been reported in other studies)
Allele or phenotype frequency
  • 1/9091 (CI: 1/4067 - 1/23073) estimated allele frequency by testing 8442 donors with D negative phenotype, screened for presence of the RHD gene in two surveys; 754 donors were C and/or E positive, the rest were ccee phenotype; 5 donors were revealed to be weakly D positive in the German population (Baden-Wurttemberg)
  • 0.171569 estimated allele frequency in individuals with D negative phenotype in the Chinese population (Shenzen area, 96% Chinese Han)
  • 0.009102 estimated allele frequency in population in the Chinese population (Shenzen area, 96% Chinese Han)
  • 0.17 calculated allele frequency in donors with D negative phenotype (adsorption-elution was not performed) Chinese Han
  • allele not observed, lowest estimate: 1/5646 estimated allele frequency in samples with D negative phenotype but C and/or E positive, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the Austrian (state of Tyrol) population
  • allele not observed, lowest estimate: 1/2326 estimated allele frequency in samples with D negative phenotype but C and/or E positive, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the Slovenian population
  • allele not observed, lowest estimate: 1/4399 estimated allele frequency in samples with D negative phenotype but C and/or E positive, screened for RHD specific sequences (in the 5'UTR region, exon 3 and exon 10) in the German (states of Lower Saxony, Saxony- Anhalt, Thuringia, Oldenburg, and Bremen) population
  • 0.076 - 0.201 estimated frequency in donors with apparent D negative phenotype (including DEL) Korean (South Korea)
  • 1/23330 (CI: 1/4926 - 1/500000) estimated allele frequency in individuals with D negative phenotype in the Austrian population, Upper Austria
  • 1/190 estimated allele frequency in the Chinese (Shanghai) population
  • 1/294 (CI: 1/1077 - 1/115) estimated allele frequency in donors with D negative phenotype United States population (Los Angeles)
  • 0,00853 cumulative allele frequency among weak D and D negative phenotypes; 0,00043 for weak D phenotype and 0,00810 for D negative phenotype in the northeastern Chinese Liaoning Province population
  • 0.012 calculated in 16,253 samples of pregnant women with D negative of weak D (2+ or less), screened for fetal RHD in the Finnish population

2D diagram

generated using Protter extraintra Met1 Met1 Ser2 Ser2 Ser3 Ser3 Lys4 Lys4 Tyr5 Tyr5 Pro6 Pro6 Arg7 Arg7 Ser8 Ser8 Val9 Val9 Arg10 Arg10 10Arg11 Arg11 Cys12 Cys12 Leu13 Leu13 Pro14 Pro14 Leu15 Leu15 Trp16 Trp16 Ala17 Ala17 Leu18 Leu18 Thr19 Thr19 Leu20 Leu20 20Glu21 Glu21 Ala22 Ala22 Ala23 Ala23 Leu24 Leu24 Ile25 Ile25 Leu26 Leu26 Leu27 Leu27 Phe28 Phe28 Tyr29 Tyr29 Phe30 Phe30 30Phe31 Phe31 Thr32 Thr32 His33 His33 Tyr34 Tyr34 Asp35 Asp35 Ala36 Ala36 Ser37 Ser37 Leu38 Leu38 Glu39 Glu39 Asp40 Asp40 40Gln41 Gln41 Lys42 Lys42 Gly43 Gly43 Leu44 Leu44 Val45 Val45 Ala46 Ala46 Ser47 Ser47 Tyr48 Tyr48 Gln49 Gln49 Val50 Val50 50Gly51 Gly51 Gln52 Gln52 Asp53 Asp53 Leu54 Leu54 Thr55 Thr55 Val56 Val56 Met57 Met57 Ala58 Ala58 Ala59 Ala59 Ile60 Ile60 60Gly61 Gly61 Leu62 Leu62 Gly63 Gly63 Phe64 Phe64 Leu65 Leu65 Thr66 Thr66 Ser67 Ser67 Ser68 Ser68 Phe69 Phe69 Arg70 Arg70 70Arg71 Arg71 His72 His72 Ser73 Ser73 Trp74 Trp74 Ser75 Ser75 Ser76 Ser76 Val77 Val77 Ala78 Ala78 Phe79 Phe79 Asn80 Asn80 80Leu81 Leu81 Phe82 Phe82 Met83 Met83 Leu84 Leu84 Ala85 Ala85 Leu86 Leu86 Gly87 Gly87 Val88 Val88 Gln89 Gln89 Trp90 Trp90 90Ala91 Ala91 Ile92 Ile92 Leu93 Leu93 Leu94 Leu94 Asp95 Asp95 Gly96 Gly96 Phe97 Phe97 Leu98 Leu98 Ser99 Ser99 Gln100 Gln100 100Phe101 Phe101 Pro102 Pro102 Ser103 Ser103 Gly104 Gly104 Lys105 Lys105 Val106 Val106 Val107 Val107 Ile108 Ile108 Thr109 Thr109 Leu110 Leu110 110Phe111 Phe111 Ser112 Ser112 Ile113 Ile113 Arg114 Arg114 Leu115 Leu115 Ala116 Ala116 Thr117 Thr117 Met118 Met118 Ser119 Ser119 Ala120 Ala120 120Leu121 Leu121 Ser122 Ser122 Val123 Val123 Leu124 Leu124 Ile125 Ile125 Ser126 Ser126 Val127 Val127 Asp128 Asp128 Ala129 Ala129 Val130 Val130 130Leu131 Leu131 Gly132 Gly132 Lys133 Lys133 Val134 Val134 Asn135 Asn135 Leu136 Leu136 Ala137 Ala137 Gln138 Gln138 Leu139 Leu139 Val140 Val140 140Val141 Val141 Met142 Met142 Val143 Val143 Leu144 Leu144 Val145 Val145 Glu146 Glu146 Val147 Val147 Thr148 Thr148 Ala149 Ala149 Leu150 Leu150 150Gly151 Gly151 Asn152 Asn152 Leu153 Leu153 Arg154 Arg154 Met155 Met155 Val156 Val156 Ile157 Ile157 Ser158 Ser158 Asn159 Asn159 Ile160 Ile160 160Phe161 Phe161 Asn162 Asn162 Thr163 Thr163 Asp164 Asp164 Tyr165 Tyr165 His166 His166 Met167 Met167 Asn168 Asn168 Met169 Met169 Met170 Met170 170His171 His171 Ile172 Ile172 Tyr173 Tyr173 Val174 Val174 Phe175 Phe175 Ala176 Ala176 Ala177 Ala177 Tyr178 Tyr178 Phe179 Phe179 Gly180 Gly180 180Leu181 Leu181 Ser182 Ser182 Val183 Val183 Ala184 Ala184 Trp185 Trp185 Cys186 Cys186 Leu187 Leu187 Pro188 Pro188 Lys189 Lys189 Pro190 Pro190 190Leu191 Leu191 Pro192 Pro192 Glu193 Glu193 Gly194 Gly194 Thr195 Thr195 Glu196 Glu196 Asp197 Asp197 Lys198 Lys198 Asp199 Asp199 Gln200 Gln200 200Thr201 Thr201 Ala202 Ala202 Thr203 Thr203 Ile204 Ile204 Pro205 Pro205 Ser206 Ser206 Leu207 Leu207 Ser208 Ser208 Ala209 Ala209 Met210 Met210 210Leu211 Leu211 Gly212 Gly212 Ala213 Ala213 Leu214 Leu214 Phe215 Phe215 Leu216 Leu216 Trp217 Trp217 Met218 Met218 Phe219 Phe219 Trp220 Trp220 220Pro221 Pro221 Ser222 Ser222 Phe223 Phe223 Asn224 Asn224 Ser225 Ser225 Ala226 Ala226 Leu227 Leu227 Leu228 Leu228 Arg229 Arg229 Ser230 Ser230 230Pro231 Pro231 Ile232 Ile232 Glu233 Glu233 Arg234 Arg234 Lys235 Lys235 Asn236 Asn236 Ala237 Ala237 Val238 Val238 Phe239 Phe239 Asn240 Asn240 240Thr241 Thr241 Tyr242 Tyr242 Tyr243 Tyr243 Ala244 Ala244 Val245 Val245 Ala246 Ala246 Val247 Val247 Ser248 Ser248 Val249 Val249 Val250 Val250 250Thr251 Thr251 Ala252 Ala252 Ile253 Ile253 Ser254 Ser254 Gly255 Gly255 Ser256 Ser256 Ser257 Ser257 Leu258 Leu258 Ala259 Ala259 His260 His260 260Pro261 Pro261 Gln262 Gln262 Gly263 Gly263 Lys264 Lys264 Ile265 Ile265 Ser266 Ser266 Lys267 Lys267 Thr268 Thr268 Tyr269 Tyr269 Val270 Val270 270His271 His271 Ser272 Ser272 Ala273 Ala273 Val274 Val274 Leu275 Leu275 Ala276 Ala276 Gly277 Gly277 Gly278 Gly278 Val279 Val279 Ala280 Ala280 280Val281 Val281 Gly282 Gly282 Thr283 Thr283 Ser284 Ser284 Cys285 Cys285 His286 His286 Leu287 Leu287 Ile288 Ile288 Pro289 Pro289 Ser290 Ser290 290Pro291 Pro291 Trp292 Trp292 Leu293 Leu293 Ala294 Ala294 Met295 Met295 Val296 Val296 Leu297 Leu297 Gly298 Gly298 Leu299 Leu299 Val300 Val300 300Ala301 Ala301 Gly302 Gly302 Leu303 Leu303 Ile304 Ile304 Ser305 Ser305 Val306 Val306 Gly307 Gly307 Gly308 Gly308 Ala309 Ala309 Lys310 Lys310 310Tyr311 Tyr311 Leu312 Leu312 Pro313 Pro313 Gly314 Gly314 Cys315 Cys315 Cys316 Cys316 Asn317 Asn317 Arg318 Arg318 Val319 Val319 Leu320 Leu320 320Gly321 Gly321 Ile322 Ile322 Pro323 Pro323 His324 His324 Ser325 Ser325 Ser326 Ser326 Ile327 Ile327 Met328 Met328 Gly329 Gly329 Tyr330 Tyr330 330Asn331 Asn331 Phe332 Phe332 Ser333 Ser333 Leu334 Leu334 Leu335 Leu335 Gly336 Gly336 Leu337 Leu337 Leu338 Leu338 Gly339 Gly339 Glu340 Glu340 340Ile341 Ile341 Ile342 Ile342 Tyr343 Tyr343 Ile344 Ile344 Val345 Val345 Leu346 Leu346 Leu347 Leu347 Val348 Val348 Leu349 Leu349 Asp350 Asp350 350Thr351 Thr351 Val352 Val352 Gly353 Gly353 Ala354 Ala354 Gly355 Gly355 Asn356 Asn356 Gly357 Gly357 Met358 Met358 Ile359 Ile359 Gly360 Gly360 360Phe361 Phe361 Gln362 Gln362 Val363 Val363 Leu364 Leu364 Leu365 Leu365 Ser366 Ser366 Ile367 Ile367 Gly368 Gly368 Glu369 Glu369 Leu370 Leu370 370Ser371 Ser371 Leu372 Leu372 Ala373 Ala373 Ile374 Ile374 Val375 Val375 Ile376 Ile376 Ala377 Ala377 Leu378 Leu378 Met379 Met379 Ser380 Ser380 380Gly381 Gly381 Leu382 Leu382 Leu383 Leu383 Thr384 Thr384 Gly385 Gly385 Leu386 Leu386 Leu387 Leu387 Leu388 Leu388 Asn389 Asn389 Leu390 Leu390 390Lys391 Lys391 Ile392 Ile392 Trp393 Trp393 Lys394 Lys394 Ala395 Ala395 Pro396 Pro396 His397 His397 Glu398 Glu398 Ala399 Ala399 Lys400 Lys400 400Tyr401 Tyr401 Phe402 Phe402 Asp403 Asp403 Asp404 Asp404 Gln405 Gln405 Val406 Val406 Phe407 Phe407 Trp408 Trp408 Lys409 Lys409 Phe410 Phe410 410Pro411 Pro411 His412 His412 Leu413 Leu413 Ala414 Ala414 Val415 Val415 Gly416 Gly416 Phe417 Phe417 417 MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF

Structure mapping

Movement    Mouse Input    Touch Input
RotationPrimary Mouse ButtonSingle touch
TranslationMiddle Mouse Button or Ctrl+PrimaryTriple touch
ZoomScroll Wheel or Second Mouse Button or Shift+PrimaryPinch (double touch)
SlabCtrl+SecondNot Available

Links

The Human RhesusBase The Human RhesusBase
Genbank: AF390110 JQ424879 EU372941 EU372942 AY751496 AY751495 AY751494 AY751493 AY751492 AY751491
Erythrogene

References

  1. International Society of Blood Transfusion et al. International Society of Blood Transfusion (ISBT) allele table Online ressource, 1935. — Online ressource — [RHeference]
  2. Okubo Y et al. A D variant, Del? Transfusion, 1984. [Citation] [RHeference]
  3. Chang JG et al. Human RhDel is caused by a deletion of 1,013 bp between introns 8 and 9 including exon 9 of RHD gene. Blood, 1998. [Citation] [RHeference]
  4. Singleton BK. Green CA et al. Two new RHD mutations associated with the DEL phenotype Transfusion Clinique et Biologique, 2001. — Abstract — [RHeference]
  5. Wagner FF et al. RHD positive haplotypes in D negative Europeans. BMC Genet, 2001. [Citation] [RHeference]
  6. Shao CP et al. Molecular background of Rh D-positive, D-negative, D(el) and weak D phenotypes in Chinese. Vox Sang, 2002. [Citation] [RHeference]
  7. Peng CT et al. Molecular basis for the RhD negative phenotype in Chinese. Int J Mol Med, 2003. [Citation] [RHeference]
  8. Chen JC et al. RHD 1227A is an important genetic marker for RhD(el) individuals. Am J Clin Pathol, 2004. [Citation] [RHeference]
  9. Shao CP et al. A new hybrid RHD-positive, D antigen-negative allele. Transfus Med, 2004. [Citation] [RHeference]
  10. Gassner C et al. Presence of RHD in serologically D-, C/E+ individuals: a European multicenter study. Transfusion, 2005. [Citation] [RHeference]
  11. Xu Q et al. Systemic analysis and zygosity determination of the RHD gene in a D-negative Chinese Han population reveals a novel D-negative RHD gene. Vox Sang, 2005. [Citation] [RHeference]
  12. Kim JY et al. Molecular characterization of D- Korean persons: development of a diagnostic strategy. Transfusion, 2005. [Citation] [RHeference]
  13. Körmöczi GF et al. A comprehensive analysis of DEL types: partial DEL individuals are prone to anti-D alloimmunization. Transfusion, 2005. [Citation] [RHeference]
  14. Luettringhaus TA et al. An easy RHD genotyping strategy for D- East Asian persons applied to Korean blood donors. Transfusion, 2006. [Citation] [RHeference]
  15. Flegel WA et al. How I manage donors and patients with a weak D phenotype. Curr Opin Hematol, 2006. [Citation] [RHeference]
  16. Shao CP et al. Multiple isoforms excluding normal RhD mRNA detected in Rh blood group Del phenotype with RHD 1227A allele. Transfus Apher Sci, 2006. [Citation] [RHeference]
  17. Nogues N et al. RHD null alleles in the Spanish population Vox Sanguinis, 2007. — Abstract — [RHeference]
  18. Yan L et al. Molecular basis of D variants in Chinese persons. Transfusion, 2007. [Citation] [RHeference]
  19. Li Q et al. Molecular basis of D variants between Uigur and Han blood donors in Xinjiang. Transfus Med, 2008. [Citation] [RHeference]
  20. Li Q et al. Molecular basis of the RHD gene in blood donors with DEL phenotypes in Shanghai. Vox Sang, 2009. [Citation] [RHeference]
  21. Polin H et al. Identification of RHD alleles with the potential of anti-D immunization among seemingly D- blood donors in Upper Austria. Transfusion, 2009. [Citation] [RHeference]
  22. Flegel WA et al. Six years' experience performing RHD genotyping to confirm D- red blood cell units in Germany for preventing anti-D immunizations. Transfusion, 2009. [Citation] [RHeference]
  23. Liu HC et al. Aberrant RNA splicing in RHD 7-9 exons of DEL individuals in Taiwan: a mechanism study. Biochim Biophys Acta, 2010. [Citation] [RHeference]
  24. Shao CP et al. Transfusion of RhD-positive blood in "Asia type" DEL recipients. N Engl J Med, 2010. [Citation] [RHeference]
  25. Christiansen M et al. RHD positive among C/E+ and D- blood donors in Denmark. Transfusion, 2010. [Citation] [RHeference]
  26. Shao CP et al. Antenatal Rh prophylaxis is unnecessary for "Asia type" DEL women. Transfus Clin Biol, 2010. [Citation] [RHeference]
  27. Wagner FF and Flegel WA et al. The Human RhesusBase Online ressource, 2011. — Online ressource — [RHeference]
  28. Mota M et al. RHD allelic identification among D-Brazilian blood donors as a routine test using pools of DNA. J Clin Lab Anal, 2012. [Citation] [RHeference]
  29. F F Wagner et al. Single Adsorption / Elution with Anti-D May Be Insufficient to Determine the D Antigen Status of Very Weak DEL Alleles Transfusion, 2012. — Abstract — [RHeference]
  30. Shao CP et al. DEL RBC transfusion should be avoided in particular blood recipient in East Asia due to allosensitization and ineffectiveness. J Zhejiang Univ Sci B, 2012. [Citation] [RHeference]
  31. Chen Q et al. Molecular basis of weak D and DEL in Han population in Anhui Province, China. Chin Med J (Engl), 2012. [Citation] [RHeference]
  32. Wagner FF et al. RHD PCR of blood donors in Northern Germany: use of adsorption/elution to determine D antigen status Vox Sanguinis, 2012. — Abstract — [RHeference]
  33. Daniels G et al. Variants of RhD--current testing and clinical consequences. Br J Haematol, 2013. [Citation] [RHeference]
  34. Haer-Wigman L et al. RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification. Transfusion, 2013. [Citation] [RHeference]
  35. Gowland P et al. Molecular RHD screening of RhD negative donors can replace standard serological testing for RhD negative donors. Transfus Apher Sci, 2014. [Citation] [RHeference]
  36. Scott SA et al. The RHD(1227G>A) DEL-associated allele is the most prevalent DEL allele in Australian D- blood donors with C+ and/or E+ phenotypes. Transfusion, 2014. [Citation] [RHeference]
  37. Wang QP et al. An investigation of secondary anti-D immunisation among phenotypically RhD-negative individuals in the Chinese population. Blood Transfus, 2014. [Citation] [RHeference]
  38. Ye SH et al. A comprehensive investigation of RHD polymorphisms in the Chinese Han population in Xi'an. Blood Transfus, 2014. [Citation] [RHeference]
  39. Gu J et al. Molecular basis of DEL phenotype in the Chinese population. BMC Med Genet, 2014. [Citation] [RHeference]
  40. Costa S et al. RHD alleles and D antigen density among serologically D- C+ Brazilian blood donors. Transfus Med, 2014. [Citation] [RHeference]
  41. Gu J et al. Analysis of density and epitopes of D antigen on the surface of erythrocytes from DEL phenotypic individuals carrying the RHD1227A allele. Blood Transfus, 2014. [Citation] [RHeference]
  42. Crottet SL et al. Implementation of a mandatory donor RHD screening in Switzerland. Transfus Apher Sci, 2014. [Citation] [RHeference]
  43. Wang M et al. Anti-D alloimmunisation in pregnant women with DEL phenotype in China. Transfus Med, 2015. [Citation] [RHeference]
  44. Ogasawara K et al. Molecular basis for D- Japanese: identification of novel DEL and D- alleles. Vox Sang, 2015. [Citation] [RHeference]
  45. He J et al. Molecular basis and zygosity determination of D variants including identification of four novel alleles in Chinese individuals. Transfusion, 2015. [Citation] [RHeference]
  46. Fichou Y et al. Extensive functional analyses of RHD splice site variants: Insights into the potential role of splicing in the physiology of Rh. Transfusion, 2015. [Citation] [RHeference]
  47. Yang HS et al. Primary anti-D alloimmunization induced by "Asian type" RHD (c.1227G>A) DEL red cell transfusion. Ann Lab Med, 2015. [Citation] [RHeference]
  48. Xu W et al. Prospective Evaluation of a Transfusion Policy of RhD-Positive Red Blood Cells into DEL Patients in China. Transfus Med Hemother, 2015. [Citation] [RHeference]
  49. Seo MH et al. An effective diagnostic strategy for accurate detection of RhD variants including Asian DEL type in apparently RhD-negative blood donors in Korea. Vox Sang, 2016. [Citation] [RHeference]
  50. Stegmann TC et al. Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women. Br J Haematol, 2016. [Citation] [RHeference]
  51. Chen DP et al. Comprehensive analysis of RHD splicing transcripts reveals the molecular basis for the weak anti-D reactivity of Del -red blood cells. Transfus Med, 2016. [Citation] [RHeference]
  52. Ji YL et al. RHD genotype and zygosity analysis in the Chinese Southern Han D+, D- and D variant donors using the multiplex ligation-dependent probe amplification assay. Vox Sang, 2017. [Citation] [RHeference]
  53. Thongbut J et al. RHD-specific microRNA for regulation of the DEL blood group: integration of computational and experimental approaches. Br J Biomed Sci, 2017. [Citation] [RHeference]
  54. Hyland CA et al. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. Pathology, 2017. [Citation] [RHeference]
  55. Jérôme Babinet et al. Erratum à l’article : « Résumés des Posters » [Transfus. Clin. Biol. 24 (2017) 3S] Transfusion Clinique et Biologique, 2018. — Abstract — [RHeference]
  56. Chun S et al. The synonymous nucleotide substitution RHD 1056C>G alters mRNA splicing associated with serologically weak D phenotype. J Clin Lab Anal, 2018. [Citation] [RHeference]
  57. Dezan MR et al. Evaluation of the applicability and effectiveness of a molecular strategy for identifying weak D and DEL phenotype among D- blood donors of mixed origin exhibiting high frequency of RHD*Ψ. Transfusion, 2018. [Citation] [RHeference]
  58. Kim B et al. Application of Multiplex Ligation-Dependent Probe Amplification Assay for Genotyping Major Blood Group Systems Including DEL Variants in the D-Negative Korean Population. Ann Lab Med, 2018. [Citation] [RHeference]
  59. Lopez GH et al. A DEL phenotype attributed to RHD Exon 9 sequence deletion: slipped-strand mispairing and blood group polymorphisms. Transfusion, 2018. [Citation] [RHeference]
  60. Zhang X et al. Molecular and computational analysis of 45 samples with a serologic weak D phenotype detected among 132,479 blood donors in northeast China. J Transl Med, 2019. [Citation] [RHeference]
  61. Wagner F. et al. Results of more than ten years testing of RhD negative first time donors by RHD PCR Transfus Med Hemother, 2019. — Abstract — [RHeference]
  62. Perez-Alvarez I et al. RHD genotyping of serologic RhD-negative blood donors in a hospital-based blood donor center. Transfusion, 2019. [Citation] [RHeference]
  63. Kim H et al. Reconsidering RhD positive blood transfusion for Asia type DEL patients. Transfus Apher Sci, 2019. [Citation] [RHeference]
  64. Sandler SG et al. Does transfusion of Asian-type DEL red blood cells to D- recipients cause D alloimmunization? Transfusion, 2019. [Citation] [RHeference]
  65. de Paula Vendrame TA et al. Characterization of RHD alleles present in serologically RHD-negative donors determined by a sensitive microplate technique. Vox Sang, 2019. [Citation] [RHeference]
  66. Stef M et al. RH genotyping by nonspecific quantitative next-generation sequencing. Transfusion, 2020. [Citation] [RHeference]
  67. Floch A et al. Comment from Rheference Online ressource, 2020. — Online ressource — [RHeference]
  68. Tammi SM et al. Next-generation sequencing of 35 RHD variants in 16 253 serologically D- pregnant women in the Finnish population. Blood Adv, 2020. [Citation] [RHeference]
  69. Thongbut J et al. Comprehensive Molecular Analysis of Serologically D-Negative and Weak/Partial D Phenotype in Thai Blood Donors. Transfus Med Hemother, 2020. [Citation] [RHeference]

Last update: Jan. 8, 2021